Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer
NCT05725343 · Mario Negri Institute for Pharmacological Research · PHASE3 · terminated · last registry update 2023-02-13 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Novartis has decided to terminate the trial due to the recent results made available from the Novartis CANOPY A study (CACZ885T2301), this decision is not related to any safety data for Canakinumab” | – | Registry record, Mario Negri Institute for Pharmacological Research |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1B in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-30Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT03447769)
- 2023-08-21Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab + Docetaxel (NCT03626545)
- 2023-07-03Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Pembrolizumab (NCT03968419)
- 2023-06-22Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Docetaxel (NCT03626545)
- 2022-08-15Also stopped (terminated): Novartis Pharmaceuticals, PDR001 + Cisplatin (NCT03064854)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision